ArticleMediators of inflammation2021
Elevated Serum Interleukin-23 Levels in Patients with Oral and Cutaneous Lichen Planus.
Article in Mediators of inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Successful treatment of generalized lichen planus with deucravacitinib monotherapy.JAAD case reports · 2026Article
- Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Clearance of Cutaneous Lichen Planus with Deucravacitinib.The Journal of clinical and aesthetic dermatology · 2026Article
- Treatment of hypertrophic lichen planus using deucravacitinib.JAAD case reports · 2024Article
- Lichen Planus: What is New in Diagnosis and Treatment?American journal of clinical dermatology · 2024Review
- Coexistence of myasthenia gravis and lichen planus: A case report and systematic review of related case reports from 1971 to 2024.Clinical case reports · 2024Article
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- Effects of interleukin-23 on the activation of mucosal-associated invariant T cells from oral lichen planus.The Journal of international medical research · 2023Article
- Comprehensive Insight into Lichen Planus Immunopathogenesis.International journal of molecular sciences · 2023Review
- Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma.Immunity, inflammation and disease · 2022Article
- Long-Term Post-COVID-19 Associated Oral Inflammatory Sequelae.Frontiers in cellular and infection microbiology · 2022Article
- Lichen Planus.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus is considered a chronic inflammatory disease which affects different sites, such as the skin, mucous membranes, hair, and nails. Based on the evidence, a complex cytokine network plays a crucial role in lichen planus pathogenesis. The study was aimed at assessing the serum IL-23 levels in the patients with cutaneous and oral lichen planus compared to healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.